In an attempt to benefit from the cost savings associated with use of generics, in June 2013 the Irish Government introduced generics substitution and reference pricing for the first time via the Health (Pricing and Supply of Medical Goods) Act. However, as perceptions of Irish patients towards generics have not been published previously, the objective of this study was to assess how generics were perceived amongst patients in the Irish health system [1].
- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
General
- Crecimiento de medicamentos genéricos en Brasil y Venezuela
- EMA launches European shortages monitoring platform to tackle persistent medicine shortages
- Penetración de los medicamentos genéricos en México y Brasil
- FDA releases one-year progress report for the Generic Drug Cluster
-
Biosimilares
Novedades
- EC approves golimumab biosimilar Gotenfia and ranibizumab biosimilar Ranluspec
- EMA recommends approval for teriparatide biosimilar Zandoriah
- FDA approves third interchangeable ranibizumab biosimilar Nufymco
- FDA approves Poherdy (first interchangeable pertuzumab) and Armlupeg (pegfilgrastim) biosimilars
Investigación
- Un estudio de la OCDE no encuentra una relación directa entre las normas de publicidad y la adopción de biosimilares
- Alcanzar los objetivos ASG en el desarrollo farmacéutico
- What is the future for the US biosimilar interchangeability designation
- Estudios de eficacia clínica en biosimilares: ¿siguen siendo necesarios?
General
- La SBR publica un posicionamiento sobre la intercambiabilidad segura entre biológicos originales y biosimilares
- Biosimilars approved in the US
- Samsung Bioepis wins Pyzchiva case; Regeneron patent rulings threaten foreign biosimilars
- Biosimilars approved in Europe
- MORE EDITORIAL SECTIONS
- Search




Post your comment